Loading…
CHLORPHENAMINE MALEATE is a brand name for Chlorpheniramine (also known as Chlorphenamine). The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Chlorphenamine Oral Solution is indicated for the symptomatic control of all allergic conditions responsive to antihistamines including hay fever, allergic rhinitis, vasomotor rhinitis, urticaria, angioneurotic oedema, food allergy, drug and serum reactions, insect bites. It is also indicated for the symptomatic…
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Do not exceed the stated dose or frequency of dosing.
Age Dose Children below 1 year:
Not recommended. 5ml (1mg) twice daily. The minimum interval between the doses should be 4 hours. Maximum daily dose: 5ml (2mg) in any 24 hours. 5ml (1mg) every 4 to 6 hours. Maximum daily dose: 15ml (6mg) in any 24 hours. Children aged 6 - 12 years: 5ml (2mg) every 4 to 6 hours.
Maximum daily dose: 30ml (12mg) in any 24 hours. Adults and children 12 years and over: 10ml (4mg) every 4 to 6 hours. Maximum daily dose: 60ml (24mg) in any 24 hours. Not recommended for children below 1 year. Special populations Elderly The elderly are more likely to experience neurological anticholinergic effects.
g. a maximum of 12mg in any 24 hours). Method of administration For oral use.
Other brands of Chlorpheniramine in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Specific estimation of the frequency of adverse events for OTC products is inherently difficult (particularly numerator data). Adverse reactions which have been observed in clinical trials and which are considered to be Common (≥1/100 to <1/10) or Very common (≥1/10) are listed below by MedDRA System Organ Class.
The frequency of other adverse events identified during post-marketing use that cannot be estimated from the available data is Not known. g. increased energy, restlessness, nervousness). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Chlorphenamine in common with other medicinal products having anticholinergic effects, should be used with caution in epilepsy, raised intra-ocular pressure including glaucoma, prostatic hypertrophy; severe hypertension or cardiovascular disease; bronchitis, bronchiectasis or asthma; hepatic impairment, renal impairment, pyloroduodenal obstruction and thyrotoxicosis.
g. increased energy, restlessness, nervousness). The anticholinergic properties of chlorphenamine may cause drowsiness, dizziness, blurred vision and psychomotor impairment in some patients which may seriously affect ability to drive and use machinery.
The effects of alcohol may be increased and therefore concurrent use should be avoided. Chlorphenamine should not be used with other antihistamine containing products, including antihistamine containing cough and cold medicines. Chlorphenamine Oral Solution contains sodium methyl parahydroxybenzoate (E219) and sodium propyl parahydroxybenzoate (E217).
These may cause allergic reactions (possibly delayed). It also contains maltitol liquid (E965). Patients with rare hereditary problems of fructose intolerance should not take this medicine.
1. The anticholinergic properties of chlorphenamine are intensified by monoamine oxidase inhibitors (MAOIs). 5).
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.